Monthly Archives: January 2011

Haiti leans on AIDS program infrastructure to rebuild health system

By on .

[podcast]http://sciencespeaksblog.org/wp-content/uploads/2011/01/Haiti-leans-on-AIDS-program-infrastructure-to-rebuild-health-system.mp3[/podcast] One testimony to the strength of the U.S. government’s AIDS program in Haiti: Four months after the devastating 2010 earthquake, the number of those treated for AIDS was at 95 percent of pre-earthquake levels. In addition, said senior U.S. health officials in a briefing to reporters, the number of pregnant women receiving AIDS treatment […]

Q & A with Dr. Vermund – Reflecting on PEPFAR Scientific Advisory Board Meeting

By on .

Sten Vermund, MD, PhD, professor of medicine and director of the Institute for Global Health at Vanderbilt University School of Medicine, sits on the Scientific Advisory Board (SAB) to the President’s Emergency Plan for AIDS Relief (PEPFAR). The SAB met for two days last week in Washington, DC, reviewing the current portfolio of PEPFAR-funded initiatives, the […]

In brief: Emanuel departs from White House post

By on .

Zeke Emanuel, MD, PhD, has returned to his station directing the Bioethics Department at the National Institutes of Health.  Dr. Emanuel joined the White House Office of Management & Budget (OMB) as a special advisor on health policy to Peter Orzag, director of the OMB, in February 2009. According to reports from Kaiser Health News and […]

Arsenic in water ups TB risk, Gel prevents HIV-like infection in monkeys and more

By on .

The following is a collection of scientific articles making headlines in HIV/TB this week: Exposure to arsenic laced water ups risk of TB: The American Journal of Epidemiology, an article entitled “Evidence from Chile that Arsenic in Drinking Water May Increase Mortality from Pulmonary Tuberculosis” looks at mortality rate ratios as compared to time patterns of arsenic […]

Abbott denied patent for liponavir/ritonavir HIV drug combo in India

By on .

The Indian patent office denied a drug patent application by U.S. pharmaceutical company Abbott Laboratories for the combination of lopinavir/ritonavir over the weekend, stating that the patenting was “not an invention.” The drug combination is a protease inhibitor used as a second line regimen to treat patients with HIV, and the patent denial opens the […]